On 1 December 2023, Ana-Maria Šimundić took up the newly created position as director of Global Medical & Clinical Affairs at Greiner Bio-One. In this role, she will represent Greiner Bio-One in national and international professional circles as well as foster exchange with experts in science and the field. Her area of responsibility includes all medical and clinical topics, such as research studies or studies related to product approvals.

Medical device manufacturer Greiner Bio-One, with headquarters in Kremsmünster (Austria), is expanding its positioning in the Preanalytics business area. The newly created Global Medical & Clinical Affairs department will assume an important interface function. This encompasses supporting development, clinical testing of new and existing products, conducting clinical trials and taking responsi­bility for the approval of products in order to further improve the safety and effectiveness of the products. Further tasks include close cooperation with healthcare institutions, physicians and medical opinion leaders, as well as product training for healthcare professionals.

Ana-Maria Šimundić, director Global Medical & Clinical Affairs, Greiner Bio-One.

Commenting on the appointment, Stefan Gebauer, head of Business Unit Preanalytics, said: “We are very pleased to have won Ana-Maria Šimundić as director of the newly created Global Medical & Clinical Affairs department. With her on board, we now have one of the world’s leading experts from the field of preanalytics in our team. She is the ideal choice for us to ensure that we can continue to offer innovative and efficient solutions that will help our customers overcome the daily challenges in the preanalytical laboratory environment.”

Šimundić is a well-known key opinion leader in Europe in laboratory diagnostics and preanalytics. She not only brings a wealth of expertise and experience in the medical and clinical field, but is also very well networked. From 2020 to 2021, she was president of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and now she is a member of the International Federation of Clinical Chemistry (IFCC) Executive Board as an EFLM representative and a former president of the EFLM board. During her time as EFLM president, she set up the EFLM Preanalytics Conference and led various working groups, for example. Most recently, she was managing director of Clinical Hospital Sveti Duh in Zagreb and Department Head of Medical Laboratory Diagnostics.

Šimundić completed her doctorate in 2003 at the Faculty of Pharmacy and Biochemistry of the University of Zagreb, where she is a university professor for laboratory medicine. She has received multiple awards for her research in the areas of preanalytics and quality management.